Morgan Stanley Cuts Target's PT To $67 As Retail Claims Another Victim
Target Corporation (NYSE: TGT) reported better-than-expected 1Q EPS, but reduced its guidance for Q2. Morgan Stanley’s Simeon Gutman maintained an Underweight rating for the company, while slashing the price target from $72 to $67. The analyst commented that the Q1 slowdown and Q2 guidance indicates that Target fell prey to the consumer/retail weakness.
Although Target’s 2016 outlook appears achievable, it is backend loaded and calls for a comp acceleration in 2H, analyst Simeon Gutman noted.
Performance in Q1
The company reported its 1Q EPS at $1.29, marginally ahead of consensus. Comps of 1.2 percent were in-line, since expectations had been lowered due to softness in the retail space and after several department stores reported disappointing results last week.
Target generated EBITDA margin expansion ex-Pharmacy to 11.5 percent. Gutman termed the performance as solid, since it was achieved despite decelerating comps in April.
The company projected comps of -2 percent to flat for Q2, significantly short of the consensus expectation of 1.8 percent. “This guidance suggests that TGT exited Q1 with negative comps, likely around 2%,” the analyst wrote.
Target guided to a ~80 bps gross margin contraction in Q2, which leaves ample room for the company to increase its promotions to clear excess inventory, particularly in apparel.
Gutman commented that the revenue slowdown is mostly related to the macro and weather conditions, and less so due to a channel or share shift.
“Recent cost reductions will be cycled next year and thus, it seems a 3% comp is needed to offset higher investments in order to maintain the 10.5% EBITDA margin goal. Without a 3% comp, EBITDA margins could begin to contract taking down TGT's EBITDA multiple along the way,” the analyst noted. He added that the long-term comp goal of 3 percent “seems increasingly elusive.”
Latest Ratings for TGT
|Sep 2016||Guggenheim||Initiates Coverage on||Neutral|
|Sep 2016||Cowen & Co.||Downgrades||Outperform||Market Perform|
|Aug 2016||Goldman Sachs||Maintains||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.